

This is not an ADB material. The views expressed in this document are the views of the author/s and/or their organizations and do not necessarily reflect the views or policies of the Asian Development Bank, or its Board of Governors, or the governments they represent. ADB does not guarantee the accuracy and/or completeness of the material's contents, and accepts no responsibility for any direct or indirect consequence of their use or reliance, whether wholly or partially. Please feel free to contact the authors directly should you have queries.

PAHO Regional Revolving Funds

Santiago Cornejo Executive Manager Regional Revolving Funds






What are the Regional Revolving Funds (RRFs)?



The RRFs are technical cooperation mechanisms that enable the Americas to equitably access quality vaccines, essential medicines, and public health supplies on time.

Through pooled procurement,
Member States obtain affordable prices
and better conditions by planning
their demand together to obtain
benefits plus reliable demand
predictability.

Scope of PAHO Regional Revolving Funds (RRFs)





PAHO's RRFs' comparative advantages



Single Point for consolidation of demand and economies of scale



Quality Guaranteed for members states and facilitator of technical support



Timely financing through its line of credit




Process facilitator and technical support for timely planning, financial projections, shipment monitoring and market signals



Transparency in processes and **alignment** in incentives



RRFs' Achievements – Securing supply



Around

50%
savings in
purchases of
vaccines, biologics
and cold chain
equipment

50%

Decrease in the prices of key ARV's

Around

Around
460M
Vaccine doses

23M

treatments and diagnostics tests in the past 2 years



years of combined experience working together with Member States

New priorities to address new challenges and lessons learned

Strengthening Innovation and Regional Manufacturing



Reduce the region's dependence on external sources of essential health products and supply chain vulnerabilities.

Establishment of regional supply agreements for rapid response



Improve preparedness and response capacities through early access to medical countermeasures.

Creation of a regional hub




Alleviate supply chain disruptions in emergency situations and reduce transportation costs

Specific initiatives



Focus support on the Elimination Initiative, Better Care for NCDs, telehealth, and high-price medicines







Regional Revolving Funds

What are the Regional Revolving Funds looking for?



Interdisciplinary approach

Management

Market Analysis
Demand Planning
Partnerships
Cross-team coordination
Strategic Communications

Country Offices

Technical Assistance Coordination with EPIs Monitoring

Procurement

Procurement processes
Logistics
Tendering and contracting
Supplier management

Technical Areas

Technical Strategies
Support to National
Programs

Regional Revolving Funds

44

Quality

Point of contact for WHO-PQ Technical evaluation Regulatory capacities Collaboration throughout the life cycle of products

Finance

Credit line holding and investment
Accounting management
Payment to manufacturers




Contracting support Legal advice




Opportunities for better prices through pooled procurement

Cancer medicines available in the SF




Strategic and Revolving Funds differences in engagement






Demand Planning and Procurement Execution Process




Total yearly procurement per Fund





Success stories: Price reduction of High-Cost Vaccines









- More than 30% cost savings since 2018.
- PAHO RF Member States have the lowest price for non-Gavi countries globally.
- Similar countries in other Regions (from 10M to 50M in population) pay 2 or 3 times the PAHO prices on average. For small countries, the cost could increase 5 to 10 times.

By promoting competition and the use of generics/biosimilars,

countries strategies to promote access to health technologies







Up to 98% in savings

Considerations and lessons learned





High capacity of administrative functions: Legal, Finance and Procurement



It needs a financial investment, and it is a great benefit to have a financial instrument



It is a technical cooperation mechanism that requires an inter-programmatic approach (programs, quality/IMT)



Today's context is more complex



Commitment and solidarity from Member States is critical

